You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Khoa Nguyen -- 2382 2023-08-22 10:52:12 |
2 Reference format revised. Lindsay Dong Meta information modification 2382 2023-08-23 02:59:24 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Nguyen, K.D.; Amerio, A.; Aguglia, A.; Magnani, L.; Parise, A.; Conio, B.; Serafini, G.; Amore, M.; Costanza, A. Microglia in Immunological Dysfunction in Schizophrenia. Encyclopedia. Available online: https://encyclopedia.pub/entry/48308 (accessed on 05 December 2025).
Nguyen KD, Amerio A, Aguglia A, Magnani L, Parise A, Conio B, et al. Microglia in Immunological Dysfunction in Schizophrenia. Encyclopedia. Available at: https://encyclopedia.pub/entry/48308. Accessed December 05, 2025.
Nguyen, Khoa D., Andrea Amerio, Andrea Aguglia, Luca Magnani, Alberto Parise, Benedetta Conio, Gianluca Serafini, Mario Amore, Alessandra Costanza. "Microglia in Immunological Dysfunction in Schizophrenia" Encyclopedia, https://encyclopedia.pub/entry/48308 (accessed December 05, 2025).
Nguyen, K.D., Amerio, A., Aguglia, A., Magnani, L., Parise, A., Conio, B., Serafini, G., Amore, M., & Costanza, A. (2023, August 22). Microglia in Immunological Dysfunction in Schizophrenia. In Encyclopedia. https://encyclopedia.pub/entry/48308
Nguyen, Khoa D., et al. "Microglia in Immunological Dysfunction in Schizophrenia." Encyclopedia. Web. 22 August, 2023.
Microglia in Immunological Dysfunction in Schizophrenia
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells12162099

Schizophrenia is a complex psychiatric condition that may involve immune system dysregulation. Microglia are the resident brain innate immune cells that have been implicated in host defense against neurotropic pathogens, brain development, and neurodegenerative disorders.

schizophrenia microglia neuroinflammation immunological dysfunction

1. Introduction

Schizophrenia (SCZ), a chronic psychiatric illness that affects approximately 24 million people worldwide, is characterized by the hallmark “positive” symptoms of hallucinations and delusions and “negative” symptoms of apathy, anhedonia, avolition, and emotional and cognitive impoverishment [1]. This debilitating disorder imposes a significant risk of physical and mental health complications, ranging from coronary heart disease to suicidal behavior (SB), highlighting reciprocal relationships between somatic psychic implications in neuro-psychiatric conditions [2]. SCZ diagnosis is difficult due to the spectral nature of the illness and the complex progression of its clinical manifestation. Patients with SCZ often present with subtle irritation/behavioral changes in the prodromal phase, followed by the onset of psychosis. Before 2013, SCZ was categorized into various subtypes (paranoid, disorganized, catatonic, undifferentiated, and residual) based on specific clinical presentations. However, this discrete division of the illness was supplemented by the concept of SCZ being a spectral disease that includes schizoaffective, schizophreniform, and schizotypal personality disorders [3].

2. Cellular Constituents of CNS Immunological Aberrations in SCZ

Following reports of elevated neuroinflammation in SCZ, an initial hypothesis stated that CNS immune disturbance may be involved in SCZ pathogenesis. The subsequent discovery of risk factors in genes associated with immune-mediated neurodevelopmental processes and the identity of CNS immune cells provided further support for the immunological origin of SCZ (Figure 1).
Figure 1. Immunological disturbances in the central nervous system (CNS) of patients with schizophrenia (SCZ). Region-specific immunological changes in CNS tissues of SCZ patients are characterized by (1) elevated expression of various activation markers of microglia (S100/A8, HLA-DR), decreased expression of neuroprotective quinolinic acid (QA), and increased microgliosis (IBA-1 density); (2) increased expression of macrophage markers (CD14 and CD163); (3) dynamic trafficking of various T cell populations (CD3/CD4/CD8); and (4) CD20+ B cell accumulation and altered B cell receptor (BCR) repertoire. Abbreviations: ACC: anterior cingulate cortex; CSF: cerebrospinal fluid; DPFC: dorsal prefrontal cortex; FC: frontal cortex; HP: hippocampus; SEZ: subependymal zone. Red font indicates discrepancies among studies.

2.1. Microglia

Microglia are the resident brain innate immune cells that have been implicated in host defense against neurotropic pathogens, brain development, and neurodegenerative disorders [4]. The growing importance of these cells in behavioral illnesses is also highlighted by the growing attention they have received in neuroimmunological investigations studying possible alterations in their distribution and function in SCZ. Given the difficulty of sampling live human microglia, cell characterization in SCZ has been mostly conducted in post mortem brain samples. One of the earliest studies of microglia in SCZ was an analysis of embryonic microglia derived from female patients with SCZ in whom these cells displayed a highly phagocytic phenotype compared to healthy controls (HCs) with no psychiatric illnesses [5]. Subsequently, morphologically activated microglia have been observed in the prefrontal cortex (PFC) and visual cortex of paranoid and chronic patients with SCZ in close proximity to dystrophic oligodendrocytes [6][7][8]. Further subcategorization of patients with SCZ revealed that this abnormal microglia activation phenotype might contribute to oligodendrocyte dystrophy in schizophrenia patients with positive symptoms [9][10], providing some of the first morphological evidence for the possible involvement of microglial activation in the development of these SCZ-associated pathologies.
In addition to these morphometric studies, others attempted to localize activation markers on microglia by immunohistochemical analysis and found increases in HLA-DR+ activated microglia in the frontal/temporal cortex and the hippocampus in patients with SCZ [11][12]. Of note, these activated microglia exhibited some degenerating features [13] and were reportedly associated with interleukin IL1β expression in the PFC [14]. Microglia activation was also observed in some of these brain regions in patients with Alzheimer’s disease (AD) and affective disorders [15][16], suggesting the possible existence of microglia reactivity against a common dysfunctional neuronal circuit among various CNS disorders. However, microglia activation in SCZ and affective disorders remains to be validated as some studies failed to detect changes in HLA-DR+ microglia in various brain regions, including PFC, anterior cingulate cortex (ACC), and hippocampus, and/or attribute this microglia activation profile to death by suicide [17][18]. Besides HLA-DR expression, a unique microglial proteome might exist in SCZ. For example, S100 calcium-binding protein (S100) A8/A9 expression [19], an inflammatory marker, was found to be upregulated in frontal cortex microglia, while quinolinic acid expression, a neuroprotective molecule, was suppressed in CA1 hippocampal microglia in patients with SCZ [20].

2.2. Other Immune Cell Types

Besides microglia, abnormalities in other immune cells have also been detected in CNS samples of SCZ patients(). For example, dynamic trafficking of adaptive immune cells in the CNS has been linked to SCZ. Whole brain immunohistochemical quantitation of T cell and B cell frequencies showed marked increases in these lymphocytes in patients with SCZ and affective disorders compared to HCs [21]. Spatial analyses also revealed region-specific alterations of these lymphocytes in SCZ brain tissues. In this regard, immunohistochemical analysis in the dorsal PFC (DPFC) revealed a reduction in CD3+ T cell density in the leptomeningeal space of subjects with SCZ compared to HCs and no significant difference in the frequencies of these lymphocytes in the gray matter of both groups.
Monophagocyte-related alterations have also been reported in SCZ brains. In the neurogenic subependymal zone (SEZ), an SCZ subgroup with high inflammation (HC) (defined by elevated expression of IL-1β, IL-1R1, serine protease inhibitor member 3 [SERPINA3], and c-x-c motif chemokine ligand 8 [CXCL8] mRNA transcripts) showed higher expression of the identity markers of macrophages (CD163) and monocytes (CD14) than high-inflammation HCs [22]. Notably, increased infiltration of monophagocytes into the SEZ appeared to be a shared pathological feature between patients with SCZ and patients with BD [23]. In the mid brain, immunostaining revealed that CD163+ macrophage density was elevated in high-inflammation SCZ compared to HCs [24].
Nevertheless, the exact role played by these brain immune cells in SCZ remains contentious. For instance, immunohistochemical analysis in the DPFC of SCZ patients yielded no evidence of CD163+CD206+ perivascular macrophage infiltration into the brain parenchyma [25]. In contrast, a different study that transcriptionally quantified CD163 mRNA expression in the DPFC showed that macrophage accumulation in this brain region was a signature of high-inflammation SCZ [26]. 
Besides post mortem brain studies, cerebrospinal fluid (CSF) analysis of adaptive and innate immune cells in SCZ is another approach that has been investigated. For example, acute psychotic symptomatology in SCZ patients [27] was associated with an accumulation of monophagocytes in CSF samples. Further analysis revealed that this signature of innate immune alteration was accompanied by an increase in the frequency of lymphocytes with an activated phenotype during psychosis onset in SCZ [28]. 

3. Alterations in Circulating Immune Cells in SCZ

3.1. Monocytes

In the innate immune system, monocytes represent the counterparts in the circulatory system of microglia and are known for their plasticity in responding to environmental changes. There is a growing body of clinical evidence of monocyte alterations in SCZ blood samples [29] (Figure 2), including higher total monocyte counts in SCZ during the first episode of psychosis, although some discrepancies remain as to whether these alterations are linked to disease severity [30][31]. A similar increase in total monocyte number was also observed in patients with non-affective psychosis [32], while elevated counts of classical monocytes and proinflammatory monocytes have been linked to clozapine-treated and recent-onset SCZ, respectively [33][34].
Cells 12 02099 g002
Figure 2. Peripheral immune alterations in patients with schizophrenia (SCZ). Major changes in immune cell types in blood samples of SCZ patients included: (1) Alterations in monocytes such as increased monocyte-to-lymphocyte and monocyte to HDL ratios (MLR and MHR), changes in expression of various immunometabolic markers (TREM1/2, HLA-DR, CD36, reactive oxygen species [ROS], GLUT1), and abnormalities in phagocytosis and cytokine production; (2) elevated expression of various neutrophil-associated markers such as neutrophil to lymphocyte ratio (NLR), oxidative stress, and phagocytosis; (3) presence of various autoantibody-producing pathogenic B cell clones, as well as increased numbers of different B cell subsets; and (4) increased activation profile of T cells (CD25), alterations in oxidative stress and T cell receptor [35] repertoire, and accumulation of immunoregulatory T lymphocyte populations, such as regulatory T (Treg), IL17-producing T-helper (Th17), and mucosal-associated invariant T (MAIT) cells. Red font indicates discrepancies among studies.
These observations of alterations in various monocyte features represent a significant breakthrough in SCZ research. While many studies inferred a monocyte-associated gene set from bulk immune cell transcriptome profiling, the studies mentioned above typically focused on a phenotypic and functional characterization of the monocytes themselves. For example, an interferon gene signature in isolated monocytes was observed in SCZ, with dynamic changes over the disease course [36]. 
Of potential clinical utility is the presence of various monocyte-specific markers for treatment response monitoring and differential diagnosis of SCZ. Specifically, reduced glucose transporter (GLUT1) expression in monocytes has been proposed as a key diagnostic feature to distinguish SCZ from BD, MDD, and autistic spectrum disorder [37], while soluble CD14, an identity marker of circulating monocytes, could accurately predict subsequent SCZ diagnosis [38]. A monocytic transcription signature was also proposed as a candidate marker for monitoring beneficial simvastatin response in patients with SCZ [39]. The effectiveness of other antipsychotics, such as haloperidol/perazin and clozapine, can also be predicted by a reduced monocyte production of I-1/TNF-α and reactive oxygen species (ROS), respectively, while the effectiveness of olanzapine could be monitored by pre-treatment monocytic expression of the fatty acid receptor CD36 [40][41][42].

3.2. Granulocytes

Circulating granulocytes consist of three major myeloid cell subsets, namely basophils, eosinophils, and neutrophils. While the first two are rarely discussed in the context of neuropsychiatric illnesses, an increase in neutrophil-related parameters represents one of the most consistent findings regarding changes in peripheral immune cells in SCZ (Figure 2).

3.3. Natural Killer Cells

NK cells are a type of immune cell with both adaptive and innate features. They have been implicated in a wide range of human diseases, ranging from infection and cancer to CNS disorders. Potential abnormalities in both NK cell count and function have been documented in SCZ, although with significant discrepancies among studies. Flow cytometric analysis showed increased counts of NK cells in clozapine-treated chronic SCZ blood samples compared to HCs [34]. In contrast, computational deconvolution based on gene expression yielded lower NK cell numbers in both drug-naïve and medicated SCZ patients [43][44], and this decrease was uncorrelated to psychotic relapse/remission. A different flow cytometric study confirmed these lower NK cell counts in chronic SCZ; however, medication appeared to increase NK cell numbers [45]. These differences could be due to the different quantification methods used (flow cytometry vs. gene expression, whole blood vs. peripheral mononuclear cells). Chronic SCZ subpopulations who received differing regimens of antipsychotic drugs may exhibit distinct NK cell profiles. In fact, an earlier study involving a heterogenous SCZ cohort (more than four subtypes and treatment modalities) failed to detect any abnormalities in immune cell counts in blood samples [46]. Regarding the function of NK cells in SCZ, there have been conflicting reports on NK cell cytolytic activity, possibly related to significant variations in general NK cell lytic function, medication regimes, and SCZ subtypes [47][48][49][50]. With regard to phenotypes, some studies suggested that an elevated expression of NK-cell-activation markers, such as HLA-DR and natural killer group 2C (NKG2C), might be associated with the first episode of psychosis in SCZ patients compared to HCs.

3.4. B Lymphocytes

Considering that various autoantibody types have been found to be elevated in serum and CSF samples of SCZ patients, B cells, as producers of antibodies, have long been implicated in the autoimmune hypothesis of SCZ (Figure 2). For instance, several small-cohort studies suggested that autoantibodies may act against anti-glutamic acid decarboxylase (GAD), γ-aminobutyric acid A receptor 1 (GABAR1), anti-acetylcholine receptor (A7ChR), and N-metil-D-aspartato receptor (NMDAR) in SCZ pathogenesis [51][52][53][54]. However, large-scale studies (n > 150) failed to confirm the biological significance of these autoantibodies in this disorder [55][56][57], or they detected only a small range of autoantibodies in low concentrations in certain SCZ subsets, such as clinically high-risk SCZ, SCZ with the first episode of psychosis, and SCZ with tardive dyskinesia.

3.5. T Lymphocytes

Numerous phenotypic studies of various circulating T cell subsets have been conducted in SCZ (Figure 2). While the findings were inconsistent with regard to the distribution of total CD3+ T cells, CD4+ helper T cells, and CD8+ cytotoxic T cells [45][58][59][60][61], they mostly agreed with regard to increased T cell activation [33][62][63]. Furthermore, activated T cells in medicated SCZ patients appeared to have higher levels of CD25 than drug-naïve patients. Along with this ex vivo-activated phenotype, several studies observed a reduced responsiveness to in vitro stimulation of IL-2 production in T cells from drug-naïve SCZ patients compared to HCs [64][65][66]. However, this decrease in IL-2 production was not observed in a study of paranoid and residual SCZ [67], possibly due to how patients were stratified in this study and/or the use of purified T cells/peripheral blood mononuclear cells vs. whole blood for in vitro assays. Regarding T-helper (Th) cell subtypes, an increase in Th2 cells was reportedly associated with the SCZ subtype with a pro-inflammatory monocyte feature [33]; however, this alteration could not be confirmed by a different study [67]. The same two studies also yielded inconsistent findings regarding the role of Th1 cells. In contrast, consensus exists regarding the elevated numbers of regulatory T cells (Treg) and IL-17-producing Th cells (Th17) in SCZ [33][62][68][69][70][71].

4. Implications for Mechanistic Studies and Therapeutic Development

To explore disease mechanisms of SCZ, various in vitro and animal studies have been established, with induced pluripotent stem cells derived from SCZ patients and rodent strains based on human genetics as the most clinically relevant attempts to model SCZ-associated pathology [72][73]. However, most immune-related studies to date have focused exclusively on the role of microglia, but not other peripheral immune cell subsets, in this psychiatric illness.
Anomalies in various immune cell subsets and their trafficking patterns in SCZ also suggest the potential utility of cell-type-specific immunotherapy as a novel pharmacological approach for this psychiatric illness [74][75]. In this regard, immunomodulators aiming to inhibit lymphocyte trafficking (fingolimod) and deplete B cells (anti-CD20 monoclonal antibody, rituximab) could significantly improve negative symptoms and general psychopathology of SCZ, respectively [76][77]. 
Besides these classical immunotherapies, the potential clinical efficacy in SCZ of other anti-inflammatory treatments, including aspirin, minocycline, N-acetylcysteine, estrogens, telmisartan (an angiotensin receptor 1 antagonist), and pioglitazone (a PPAR-γ antagonist) [78][79][80], has been observed. Interestingly, other anti-inflammatory medications, such as celecoxib, davunetide, dextromethorphan, fatty acids, pregnenolone, statins, and varenicline, did not have a significant impact on SCZ symptoms in a recent meta-analysis, highlighting the presence of inflammatory-pathway-specific abnormalities in SCZ development. 

References

  1. Faden, J.; Citrome, L. Schizophrenia: One name, many different manifestations. Med. Clin. N. Am. 2023, 107, 61–72.
  2. Costanza, A.; Baertschi, M.; Weber, K.; Canuto, A. Maladies neurologiques et suicide: De la neurobiology au manque d’éspoir . Rev. Med. Suisse 2015, 11, 402–405.
  3. Lewine, R.; Hart, M. Schizophrenia spectrum and other psychotic disorders. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2020; pp. 315–333.
  4. Kierdorf, K.; Masuda, T.; Jordão, M.J.C.; Prinz, M. Macrophages at cns interfaces: Ontogeny and function in health and disease. Nat. Rev. Neurosci. 2019, 20, 547–562.
  5. Solov’eva, Z.; Orlovskaia, D.D. Microglia-type cells in normal and pathologic human embryonic brains. Zhurnal Nevropatol. I Psikhiatrii Im. SS Korsakova 1979, 79, 852–857.
  6. Uranova, N.A.; Vikhreva, O.V.; Rakhmanova, V.I.; Orlovskaya, D.D. Ultrastructural pathology of oligodendrocytes in the white matter in continuous paranoid schizophrenia: A role for microglia. Zhurnal Nevropatol. I Psikhiatrii Im. SS Korsakova 2017, 117, 76.
  7. Uranova, N.A.; Zimina, I.S.; Vikhreva, O.V.; Krukov, N.O.; Rachmanova, V.I.; Orlovskaya, D.D. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J. Biol. Psychiatry 2010, 11, 567–578.
  8. Vikhreva, O.V.; Rakhmanova, V.I.; Orlovskaya, D.D.; Uranova, N.A. Ultrastructural pathology of oligodendrocytes in white matter in continuous attack-like schizophrenia and a role for microglia. Zhurnal Nevropatol. I Psikhiatrii Im. SS Korsakova 2018, 118, 69.
  9. Uranova, N.A.; Vikhreva, O.V.; Rakhmanova, V.I.; Orlovskaya, D.D. Ultrastructural pathology of oligodendrocytes adjacent to microglia in prefrontal white matter in schizophrenia. NPJ Schizophr. 2018, 4, 26.
  10. Uranova, N.A.; Vikhreva, O.V.; Rakhmanova, V.I.; Orlovskaya, D.D. Dystrophy of oligodendrocytes and adjacent microglia in prefrontal gray matter in schizophrenia. Front. Psychiatr. 2020, 11, 204.
  11. Busse, S.; Busse, M.; Schiltz, K.; Bielau, H.; Gos, T.; Brisch, R.; Mawrin, C.; Schmitt, A.; Jordan, W.; Müller, U.J.; et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations? Brain Behav. Immun. 2012, 26, 1273–1279.
  12. Radewicz, K.; Garey, L.J.; Gentleman, S.M.; Reynolds, R. Increase in hla-dr immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59, 137–150.
  13. Wierzba-Bobrowicz, T.; Lewandowska, E.; Kosno-Kruszewska, E.; Lechowicz, W.; Pasennik, E.; Schmidt-Sidor, B. Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. 2004, 42, 157–165.
  14. Fillman, S.G.; Cloonan, N.; Catts, V.S.; Miller, L.C.; Wong, J.; McCrossin, T.; Cairns, M.; Weickert, C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2012, 18, 206–214.
  15. Bayer, T.A.; Buslei, R.; Havas, L.; Falkai, P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999, 271, 126–128.
  16. Costanza, A.; Xekardaki, A.; Kovari, E.; Gold, G.; Bouras, C.; Giannakopoulos, P. Microvascular burden and alzheimer-type lesions across the age spectrum. J. Alzheimers Dis. 2012, 32, 643–652.
  17. Steiner, J.; Bielau, H.; Brisch, R.; Danos, P.; Ullrich, O.; Mawrin, C.; Bernstein, H.-G.; Bogerts, B. Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42, 151–157.
  18. Steiner, J.; Mawrin, C.; Ziegeler, A.; Bielau, H.; Ullrich, O.; Bernstein, H.-G.; Bogerts, B. Distribution of hla-dr-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 2006, 112, 305–316.
  19. Foster, R.; Kandanearatchi, A.; Beasley, C.; Williams, B.; Khan, N.; Fagerhol, M.K.; Everall, I.P. Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: Evidence for an inflammatory process? Eur. J. Neurosci. 2006, 24, 3561–3566.
  20. Gos, T.; Myint, A.-M.; Schiltz, K.; Meyer-Lotz, G.; Dobrowolny, H.; Busse, S.; Müller, U.J.; Mawrin, C.; Bernstein, H.-G.; Bogerts, B.; et al. Reduced microglial immunoreactivity for endogenous nmda receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain Behav. Immun. 2014, 41, 59–64.
  21. Schlaaff, K.; Dobrowolny, H.; Frodl, T.; Mawrin, C.; Gos, T.; Steiner, J.; Bogerts, B. Increased densities of t and b lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients. Brain Behav. Immun. 2020, 88, 497–506.
  22. North, H.F.; Weissleder, C.; Fullerton, J.M.; Webster, M.J.; Weickert, C.S. Increased immune cell and altered microglia and neurogenesis transcripts in an australian schizophrenia subgroup with elevated inflammation. Schizophr. Res. 2022, 248, 208–218.
  23. North, H.F.; Weissleder, C.; Fullerton, J.M.; Sager, R.; Webster, M.J.; Weickert, C.S. A schizophrenia subgroup with elevated inflammation displays reduced microglia, increased peripheral immune cell and altered neurogenesis marker gene expression in the subependymal zone. Transl. Psychiatry 2021, 11, 635.
  24. Purves-Tyson, T.D.; Robinson, K.; Brown, A.M.; Boerrigter, D.; Cai, H.Q.; Weissleder, C.; Owens, S.J.; Rothmond, D.A.; Shannon Weickert, C. Increased macrophages and c1qa, c3, c4 transcripts in the midbrain of people with schizophrenia. Front. Immunol. 2020, 11, 2002.
  25. De Picker, L.J.; Victoriano, G.M.; Richards, R.; Gorvett, A.J.; Lyons, S.; Buckland, G.R.; Tofani, T.; Norman, J.L.; Chatelet, D.S.; Nicoll, J.A.R.; et al. Immune environment of the brain in schizophrenia and during the psychotic episode: A human post-mortem study. Brain Behav. Immun. 2021, 97, 319–327.
  26. Zhu, Y.; Webster, M.J.; Murphy, C.E.; Middleton, F.A.; Massa, P.T.; Liu, C.; Dai, R.; Weickert, C.S. Distinct phenotypes of inflammation associated macrophages and microglia in the prefrontal cortex schizophrenia compared to controls. Front. Neurosci. 2022, 16, 858989.
  27. Nikkilä, H.V.; Müller, K.; Ahokas, A.; Miettinen, K.; Rimón, R.; Andersson, L.C. Accumulation of macrophages in the csf of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry 1999, 156, 1725–1729.
  28. Nikkilä, H.V.; Müller, K.; Ahokas, A.; Rimón, R.; Andersson, L.C. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr. Res. 2001, 49, 99–105.
  29. Mazza, M.G.; Capellazzi, M.; Lucchi, S.; Tagliabue, I.; Rossetti, A.; Clerici, M. Monocyte count in schizophrenia and related disorders: A systematic review and meta-analysis. Acta Neuropsychiatr. 2020, 32, 229–236.
  30. Orhan, F.; Schwieler, L.; Fatouros-Bergman, H.; Malmqvist, A.; Cervenka, S.; Collste, K.; Flyckt, L.; Farde, L.; Sellgren, C.M.; Piehl, F.; et al. Increased number of monocytes and plasma levels of mcp-1 and ykl-40 in first-episode psychosis. Acta Psychiatr. Scand. 2018, 138, 432–440.
  31. Steiner, J.; Frodl, T.; Schiltz, K.; Dobrowolny, H.; Jacobs, R.; Fernandes, B.S.; Guest, P.C.; Meyer-Lotz, G.; Borucki, K.; Bahn, S.; et al. Innate immune cells and c-reactive protein in acute first-episode psychosis and schizophrenia: Relationship to psychopathology and treatment. Schizophr. Bull. 2020, 46, 363–373.
  32. Miller, B.J.; Kandhal, P.; Rapaport, M.H.; Mellor, A.; Buckley, P. Total and differential white blood cell counts, high-sensitivity c-reactive protein, and cardiovascular risk in non-affective psychoses. Brain Behav. Immun. 2015, 45, 28–35.
  33. Drexhage, R.C.; Hoogenboezem, T.A.; Cohen, D.; Versnel, M.A.; Nolen, W.A.; van Beveren, N.J.M.; Drexhage, H.A. An activated set point of t-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int. J. Neuropsychopharmacol. 2011, 14, 746–755.
  34. Fernandez-Egea, E.; Vértes, P.E.; Flint, S.M.; Turner, L.; Mustafa, S.; Hatton, A.; Smith, K.G.C.; Lyons, P.A.; Bullmore, E.T. Peripheral immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. PLoS ONE 2016, 11, e0155631.
  35. Whitcroft, K.L.; Hummel, T. Olfactory dysfunction in COVID-19. JAMA 2020, 323, 2512.
  36. Melbourne, J.K.; Rosen, C.; Chase, K.A.; Feiner, B.; Sharma, R.P. Monocyte transcriptional profiling highlights a shift in immune signatures over the course of illness in schizophrenia. Front. Psychiatr. 2021, 12, 649494.
  37. Zaki, J.K.; Lago, S.G.; Rustogi, N.; Gangadin, S.S.; Benacek, J.; van Rees, G.F.; Haenisch, F.; Broek, J.A.; Suarez-Pinilla, P.; Ruland, T.; et al. Diagnostic model development for schizophrenia based on peripheral blood mononuclear cell subtype-specific expression of metabolic markers. Transl. Psychiatry 2022, 12, 457.
  38. Weber, N.S.; Gressitt, K.L.; Cowan, D.N.; Niebuhr, D.W.; Yolken, R.H.; Severance, E.G. Monocyte activation detected prior to a diagnosis of schizophrenia in the us military new onset psychosis project (mnopp). Schizophr. Res. 2018, 197, 465–469.
  39. Aichholzer, M.; Gangadin, S.S.; Sommer, I.E.C.; Wijkhuis, A.; de Witte, L.D.; Kahn, R.S.; Bahn, S.; Drexhage, H.A.; Schiweck, C. Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial. Brain Behav. Immun.—Health 2022, 26, 100551.
  40. Kowalski, J.; Blada, P.; Kucia, K.; Madej, A.; Herman, Z.S. Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Schizophr. Res. 2001, 50, 169–175.
  41. Gross, A.; Joffe, G.; Joutsiniemi, S.-L.; Nyberg, P.; Rimón, R.; Appelberg, B. Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with eeg slowing in schizophrenic patients. Neuropsychobiology 2003, 47, 73–77.
  42. Tomasik, J.; Schwarz, E.; Lago, S.G.; Rothermundt, M.; Leweke, F.M.; van Beveren, N.J.M.; Guest, P.C.; Rahmoune, H.; Steiner, J.; Bahn, S. Pretreatment levels of the fatty acid handling proteins h-fabp and cd36 predict response to olanzapine in recent-onset schizophrenia patients. Brain Behav. Immun. 2016, 52, 178–186.
  43. Karpiński, P.; Frydecka, D.; Sąsiadek, M.M.; Misiak, B. Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder. Brain Behav. Immun. 2016, 54, 194–200.
  44. Karpiński, P.; Samochowiec, J.; Frydecka, D.; Sąsiadek, M.M.; Misiak, B. Further evidence for depletion of peripheral blood natural killer cells in patients with schizophrenia: A computational deconvolution study. Schizophr. Res. 2018, 201, 243–248.
  45. Sperner-Unterweger, B.; Whitworth, A.; Kemmler, G.; Hilbe, W.; Thaler, J.; Weiss, G.; Fleischhacker, W.W. T-cell subsets in schizophrenia: A comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res. 1999, 38, 61–70.
  46. Rudolf, S.; Schlenke, P.; Broocks, A.; Peters, M.; Rothermundt, M.; Arolt, V.; Kirchner, H. Search for atypical lymphocytes in schizophrenia. World J. Biol. Psychiatry 2004, 5, 33–37.
  47. Abdeljaber, M.H.; Nair, M.P.N.; Schork, M.A.; Schwartz, S.A. Depressed natural killer cell activity in schizophrenic patients. Immunol. Investig. 1994, 23, 259–268.
  48. DeLisi, L.E.; Ortaldo, J.R.; Maluish, A.E.; Wyatt, R.J. Deficient natural killer cell (nk) activity and macrophage functioning in schizophrenic patients. J. Neural Transm. 1983, 58, 99–106.
  49. McDaniel, J.; Jewart, R.; Eccard, M.; Pollard, W.; Caudle, J.; Stipetic, M.; Risby, E.; Lewine, R.; Risch, S. Natural killer cell activity in schizophrenia and schizoaffective disorder: A pilot study. Schizophr. Res. 1992, 8, 125–128.
  50. Yovel, G.; Sirota, P.; Mazeh, D.; Shakhar, G.; Rosenne, E.; Ben-Eliyahu, S. Higher natural killer cell activity in schizophrenic patients: The impact of serum factors, medication, and smoking. Brain Behav. Immun. 2000, 14, 153–169.
  51. Chandley, M.J.; Miller, M.N.; Kwasigroch, C.N.; Wilson, T.D.; Miller, B.E. Increased antibodies for the α7 subunit of the nicotinic receptor in schizophrenia. Schizophr. Res. 2009, 109, 98–101.
  52. Keshavarz, F.; Soltani, M.; Mokhtarian, K.; Beshkar, P.; Majidi, J.; Azadegan-Dehkordi, F.; Anjomshoa, M.; Bagheri, N. Autoantibodies against central nervous system antigens and the serum levels of il-32 in patients with schizophrenia. Neuroimmunomodulation 2022, 29, 493–499.
  53. Shiwaku, H.; Nakano, Y.; Kato, M.; Takahashi, H. Detection of autoantibodies against gabaarα1 in patients with schizophrenia. Schizophr. Res. 2020, 216, 543–546.
  54. Soltani, M.; Beshkar, P.; Mokhtarian, K.; Anjomshoa, M.; Mohammad Rezaei, M.; Azadegan-Dehkordi, F.; Mirzaei, Y.; Majidi, J.; Bagheri, N. A study of autoantibodies against some central nervous system antigens and the il-35 serum level in schizophrenia. Iran. J. Allergy Asthma Immunol. 2022, 21, 441–448.
  55. Hallford, P.; Clair, D.S.; Halley, L.; Mustard, C.; Wei, J. A study of type-1 diabetes associated autoantibodies in schizophrenia. Schizophr. Res. 2016, 176, 186–190.
  56. Hoffmann, C.; Stevens, J.; Zong, S.; van Kruining, D.; Saxena, A.; Küçükali, C.İ.; Tüzün, E.; Yalçınkaya, N.; De Hert, M.; González-Vioque, E.; et al. Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder. PLoS ONE 2018, 13, e0208412.
  57. Zhou, D.; Xie, C.; Li, X.; Song, N.; Kou, Z.; Zhang, T.; Yuan, T.-F. Rare presence of autoantibodies targeting to nmda and gabaa receptors in schizophrenia patients. Schizophr. Res. 2022, 249, 93–97.
  58. Steiner, J.; Jacobs, R.; Panteli, B.; Brauner, M.; Schiltz, K.; Bahn, S.; Herberth, M.; Westphal, S.; Gos, T.; Walter, M.; et al. Acute schizophrenia is accompanied by reduced t cell and increased b cell immunity. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260, 509–518.
  59. Müller, N.; Hofschuster, E.; Ackenheil, M.; Eckstein, R. T-cells and psychopathology in schizophrenia: Relationship to the outcome of neuroleptic therapy. Acta Psychiatr. Scand. 1993, 87, 66–71.
  60. Saĭfulina, N.A.; Arkhipov, G.S.; Stepanov, A.F.; Gusev Iu, A. T- and b-lymphocytes and their clinico-pathogenetic significance in patients with paranoid schizophrenia. Zhurnal Nevropatol. I Psikhiatrii Im. SS Korsakova 1990, 90, 87–90.
  61. Achiron, A.; Noy, S.; Pras, E.; Lereya, J.; Hermesh, H.; Laor, N. T-cell subsets in acute psychotic schizophrenic patients. Biol. Psychiatry 1994, 35, 27–31.
  62. Sahbaz, C.; Zibandey, N.; Kurtulmus, A.; Duran, Y.; Gokalp, M.; Kırpınar, I.; Sahin, F.; Guloksuz, S.; Akkoc, T. Reduced regulatory t cells with increased proinflammatory response in patients with schizophrenia. Psychopharmacology 2020, 237, 1861–1871.
  63. Theodoropoulou, S.; Spanakos, G.; Baxevanis, C.N.; Economou, M.; Gritzapis, A.D.; Papamichail, M.P.; Stefanis, C.N. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res. 2001, 47, 13–25.
  64. Bessler, H.; Levental, Z.; Karp, L.; Modai, I.; Djaldetti, M.; Weizman, A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry 1995, 38, 297–302.
  65. Villemain, F.; Chatenoud, L.; Galinowski, A.; Homo-Delarche, F.; Ginestet, D.; Loo, H.; Zarifian, E.; Bach, J.F. Aberrant t cell-mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production. Am. J. Psychiatry 1989, 146, 609–616.
  66. Yang Zhang, X.; Feng Zhou, D.; Yuan Cao, L.; Yan Zhang, P.; Ying Wu, G. Decreased production of interleukin-2 (il-2), il-2 secreting cells and cd4+ cells in medication-free patients with schizophrenia. J. Psychiatr. Res. 2002, 36, 331–336.
  67. Wilke, I.; Arolt, V.; Rothermundt, M.; Weitzsch, C.; Hornberg, M.; Kirchner, H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246, 279–284.
  68. Borovcanin, M.M.; Minic Janicijevic, S.; Jovanovic, I.P.; Gajovic, N.M.; Jurisevic, M.M.; Arsenijevic, N.N. Type 17 immune response facilitates progression of inflammation and correlates with cognition in stable schizophrenia. Diagnostics 2020, 10, 926.
  69. Ding, M.; Song, X.; Zhao, J.; Gao, J.; Li, X.; Yang, G.; Wang, X.; Harrington, A.; Fan, X.; Lv, L. Activation of th17 cells in drug naïve, first episode schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 51, 78–82.
  70. Kelly, D.L.; Li, X.; Kilday, C.; Feldman, S.; Clark, S.; Liu, F.; Buchanan, R.W.; Tonelli, L.H. Increased circulating regulatory t cells in medicated people with schizophrenia. Psychiatry Res. 2018, 269, 517–523.
  71. Varun, C.N.; Venkataswamy, M.M.; Ravikumar, R.; Nagaraju, R.; Debnath, M.; Varambally, S.; Venkatasubramanian, G.; Ravi, V. Th17 and mait cell mediated inflammation in antipsychotic free schizophrenia patients. Schizophr. Res. 2019, 212, 47–53.
  72. Farsi, Z.; Sheng, M. Molecular mechanisms of schizophrenia: Insights from human genetics. Curr. Opin. Neurobiol. 2023, 81, 102731.
  73. Sheridan, S.D.; Horng, J.E.; Perlis, R.H. Patient-Derived In Vitro Models of Microglial Function and Synaptic Engulfment in Schizophrenia. Biol. Psychiatry 2022, 92, 470–479.
  74. Chauhan, P.; Kaur, G.; Prasad, R.; Singh, H. Pharmacotherapy of schizophrenia: Immunological aspects and potential role of immunotherapy. Expert Rev. Neurother. 2021, 21, 1441–1453.
  75. Miller, B.J.; Goldsmith, D.R. Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions. Neuropsychopharmacology 2017, 42, 299–317.
  76. Bejerot, S.; Sigra Stein, S.; Welin, E.; Eklund, D.; Hylén, U.; Humble, M.B. Rituximab as an Adjunctive Treatment for Schizophrenia Spectrum Disorder or Obsessive-Compulsive Disorder: Two Open-Label Pilot Studies on Treatment-Resistant Patients. J. Psychiatr. Res. 2023, 158, 319–329.
  77. Karbalaee, M.; Jameie, M.; Amanollahi, M.; TaghaviZanjani, F.; Parsaei, M.; Basti, F.A.; Mokhtari, S.; Moradi, K.; Ardakani, M.-R.K.; Akhondzadeh, S. Efficacy and Safety of Adjunctive Therapy with Fingolimod in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Schizophr. Res. 2023, 254, 92–98.
  78. Fan, X.; Song, X.; Zhao, M.; Jarskog, L.F.; Natarajan, R.; Shukair, N.; Freudenreich, O.; Henderson, D.C.; Goff, D.C. The Effect of Adjunctive Telmisartan Treatment on Psychopathology and Cognition in Patients with Schizophrenia. Acta Psychiatr. Scand. 2017, 136, 465–472.
  79. Sagheddu, C.; Melis, M.; Muntoni, A.L.; Pistis, M. Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. Pharmaceuticals 2021, 14, 1025.
  80. Çakici, N.; van Beveren, N.J.M.; Judge-Hundal, G.; Koola, M.M.; Sommer, I.E.C. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis. Psychol. Med. 2019, 49, 2307–2319.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Psychology, Biological
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Khoa D. Nguyen , Andrea Amerio , Andrea Aguglia , Luca Magnani ,
Alberto Parise
,
Benedetta Conio
, Gianluca Serafini ,
Mario Amore
, Alessandra Costanza
View Times: 733
Revisions: 2 times (View History)
Update Date: 23 Aug 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback